Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115779 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Yoshimasa Shiraishi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chugai Pharmaceutical Co Ltd.
Abstract (Originalsprache)
BACKGROUND: Individuals with thyroid transcription factor-1 (TTF-1)-negative nonsquamous non-small cell lung cancer (NSCLC) have a poor prognosis. There have been no prospective studies targeting TTF-1-negative nonsquamous NSCLC. METHODS: This multicenter, single-arm phase 2 study enrolled chemotherapy-naïve individuals with TTF-1-negative advanced nonsquamous NSCLC to receive four cycles of atezolizumab in combination with carboplatin plus nab-paclitaxel, followed by atezolizumab alone. The primary endpoint was progression-free survival (PFS). RESULTS: Between June 2022 and March 2024, 52 patients (41 male and 11 female) with a median age of 68.0 years were enrolled. Thirty-three patients had adenocarcinoma and 19 had nonadenocarcinoma. Nineteen, 30, and 3 patients were current, former, and never-smokers, respectively. The PD-L1 tumor proportion score was < 1 % in 22 cases, 1-49 % in 18 cases, ≥ 50 % in 11 cases, and unknown in 1 case. The median PFS was 4.9 months (80 % confidence interval [CI], 4.3-5.9 months). The lower limit of the 80 % CI did not exceed the prespecified threshold of 4.5 months; therefore, the study did not meet its primary endpoint. The median overall survival was 13.2 months (95 % CI, 10.3-27.2 months). The response rate was 56.9 % (95 % CI, 43.3-69.5 %). There were no new safety signals. CONCLUSIONS: This first prospective study of individuals with TTF-1-negative advanced nonsquamous NSCLC has provided evidence for the efficacy and safety of the combination of carboplatin plus nab-paclitaxel with atezolizumab in such patients. The prognosis of TTF-1-negative advanced nonsquamous NSCLC remains poor, however, warranting further treatment development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
- Department of Statistics and Data Center, Clinical Research Support Center Kyushu, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan.
- Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, Fukuoka 802-0077, Japan.
- Department of Thoracic Medical Oncology, Oita Prefectural Hospital, 2-8-1 Bunyo, Oita 870-8511, Japan.
- Department of Respiratory Medicine, Fukuoka University Hospital, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
Förderung
- Chugai Pharmaceutical Co Ltd
Zitieren
APA
Shiraishi, Y., Shimose, T., Tachihara, M., Tsuchiya-Kawano, Y., Morinaga, R., Inoue, H., Toi, Y., Yamada, T., Yamaguchi, M., Kashiwabara, K., Tobino, K., Ishii, H., Sakata, Y., Inaba, M., Nakashima, K., Chibana, K., Fukui, T., Izumi, M., Saito, R., …, & Okamoto, I. (2025). Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115779
Vancouver
Shiraishi Y, Shimose T, Tachihara M, Tsuchiya-Kawano Y, Morinaga R, Inoue H, et al. Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102). European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115779
BibTeX
@article{Shiraishi2025,
author = {Shiraishi, Yoshimasa and Shimose, Takayuki and Tachihara, Motoko and Tsuchiya-Kawano, Yuko and Morinaga, Ryotaro and Inoue, Hiroyuki and Toi, Yukihiro and Yamada, Tadaaki and Yamaguchi, Masafumi and Kashiwabara, Kosuke and Tobino, Kazunori and Ishii, Hidenobu and Sakata, Yoshihiko and Inaba, Megumi and Nakashima, Kazuhisa and Chibana, Kenji and Fukui, Tomoya and Izumi, Miiru and Saito, Ryota and Ishii, Hiroshi and Omori, Shota and Ogusu, Shinsuke and Furuyama, Kazuto and Miura, Satoru and Harada, Taishi and Okamoto, Isamu},
title = {Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115779}
}
EUVIMED